Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mind Medicine Mindmed Inc (NQ: MNMD ) 6.610 +0.190 (+2.96%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Mind Medicine Mindmed Inc < Previous 1 2 3 4 5 6 7 8 9 ... 31 32 Next > Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week September 15, 2024 The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come. Via Talk Markets Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th September 10, 2024 While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are... Via Talk Markets MindMed Announces New Employee Inducement Grants September 09, 2024 From Mind Medicine Inc. Via Business Wire Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August September 06, 2024 The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a... Via Talk Markets Psychedelics Company MindMed Prices Public Offering Aiming To Raise $75M August 12, 2024 Via Benzinga Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration September 05, 2024 The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development. Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence MindMed to Participate in September Investor Conferences September 04, 2024 From Mind Medicine Inc. Via Business Wire Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week August 24, 2024 Opportunities to invest in psychedelic stocks are emerging for those willing to get in early, and the 4 largest psychedelic compound-based portfolio drug discovery companies are up 5.9% in the past... Via Talk Markets Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD August 15, 2024 This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies with their stock performances MTD, in July, their areas of focus, and their latest... Via Talk Markets MNMD Stock Earnings: Mind Medicine Misses EPS for Q2 2024 August 13, 2024 MNMD stock results show that Mind Medicine missed analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace MindMed Reports Second Quarter 2024 Financial Results and Business Updates August 13, 2024 From Mind Medicine Inc. Via Business Wire Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering August 09, 2024 From Mind Medicine (MindMed) Inc. Via Business Wire Mind Medicine (MindMed) Inc. Announces Proposed Public Offering August 09, 2024 From Mind Medicine (MindMed) Inc. Via Business Wire MindMed to Present at Canaccord Genuity’s 44th Annual Growth Conference August 06, 2024 From Mind Medicine Inc. Via Business Wire MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update August 06, 2024 From Mind Medicine Inc. Via Business Wire EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves July 31, 2024 Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy. Via Benzinga MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer July 29, 2024 From Mind Medicine Inc. Via Business Wire MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT) July 17, 2024 From Mind Medicine Inc. Via Business Wire Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD July 14, 2024 The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... Via Talk Markets 3 Psychedelic Stocks to Ride to the Moon and Beyond July 06, 2024 Psychedelic stocks are a hot, trending area of investment as the FDA continues to weigh regulatory considerations that will open the market. Via InvestorPlace Exposures Product Safety FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals July 04, 2024 Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals. Via InvestorPlace Exposures Product Safety Clinical-Stage BioTech Drug Stocks Declined 13% In June July 01, 2024 Our BioTech Drug Stocks Portfolio was DOWN 13.2% in June. Before proceeding read Via Talk Markets MindMed to be Included in Russell 2000® and Russell 3000® Indexes June 28, 2024 From Mind Medicine Inc. Via Business Wire Groundbreaking Fentanyl Vaccine Being Developed To Prevent Fatal Overdoses, Startup Secures $10M June 26, 2024 The initiative focuses on commercializing academic research aimed at preventing deadly fentanyl from reaching the brain. Via Benzinga Largest Clinical-Stage BioTech Drug Stocks Declined 6% June 22, 2024 Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they... Via Talk Markets MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference June 21, 2024 From Mind Medicine Inc. Via Business Wire MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD) June 20, 2024 From Mind Medicine Via Business Wire Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024 June 18, 2024 Discover top strong buy penny stocks, poised for impressive gains as market indices climb, offering unique opportunities. Via InvestorPlace Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why June 09, 2024 Stocks for companies developing psychedelic treatments fell last Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA. Via Talk Markets Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment June 05, 2024 FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision. Via Benzinga Exposures Product Safety < Previous 1 2 3 4 5 6 7 8 9 ... 31 32 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.